Study #2024-0279
CTX-009 with gemcitabine, cisplatin, and durvalumab as first-line therapy in patients with unresectable or metastatic biliary tract cancers
MD Anderson Study Status
Enrolling
Treatment Agent
Gemcitabine, Cisplatin, Durvalumab, CTX-009
Description
To evaluate combination therapy of adding CTX-009 to the standard therapy GCD as first-line therapy in patients with unresectable or mBTC.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Biliary Tract Cancer
Study phase:
Physician name:
Ian Hu
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-833-391-3015
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.